For years, telemedicine providers who want to prescribe controlled substances to a new patient without any prior in-person evaluation have run into a gap in federal law: the Ryan Haight Act generally requires such an evaluation unless a narrow exception applies, but the exception meant to address this — a "special registration" for telemedicine — was never finalized by the DEA. The agency's more recent proposed rule is an attempt to finally fill that gap.
What the special registration would do
The concept behind special registration is to create a distinct DEA registration category specifically for telemedicine prescribing of controlled substances, separate from the standard registration tied to a physical practice location. In principle, a physician holding this registration could prescribe certain controlled substances to a patient they have only ever evaluated remotely, without the in-person visit that current law otherwise contemplates.
Why it has taken so long
The Ryan Haight Act directed the DEA to establish special registration rules back in 2008, but the agency did not issue a proposal for many years. Temporary pandemic-era flexibilities allowed telemedicine prescribing of controlled substances without an in-person evaluation, and as those flexibilities have been extended and revisited, pressure has grown on the DEA to finalize a permanent framework rather than continuing to rely on temporary extensions.
Special registration has been on the books since 2008 but never finalized — pandemic-era flexibility is what has actually kept telemedicine controlled-substance prescribing functioning in the meantime.
What the proposal would not change
A federal special registration would address DEA registration and the in-person evaluation requirement under federal law. It generally would not override state-level controlled substance prescribing rules, state medical board requirements, or state licensure obligations, all of which continue to apply independently. A physician holding a special registration would still typically need to hold an appropriate medical license in the state where the patient is located.
What physicians are watching for
Key open questions in the rulemaking process include which drug schedules would be eligible, whether there would be limits on prescribing volume or duration without an eventual in-person visit, and what documentation or monitoring requirements would apply. Because the rule has moved through multiple drafts and extensions, physicians who prescribe controlled substances via telehealth generally keep an eye on both DEA announcements and the current state of any temporary flexibilities.
This rulemaking has changed direction multiple times and remains in progress, so requirements vary by state and change over time — always confirm current requirements directly with the relevant state board or agency before making a compliance decision.